

Supplementary Data


1. Supplementary Data 1. Search keyword

(“Resistant hypertension” OR “refractory hypertension”) AND (Eplerenone OR Spironolactone OR “Mineralocorticoid receptor antagonist”)


2. Supplementary Figure 1. Risk of Bias of the Studies

	Randomisation Process	Deviations From the intended intervention	Missing Outcome Data	Measurement of Outcome	Selection of the reported result	Overall	
Yang 2016 ¹	+	+	+	!	+	!	+ : Low risk
Václavík 2011 ²	+	+	!	+	!	!	
Tsujimoto 2020 ³	+	+	+	+	!	!	! : Some concerns
Krasińska 2019 ⁴	+	+	+	+	!	!	
Schneider 2017 ⁵	+	+	+	+	!	!	- : High risk
Spence 2017 ⁶	+	+	+	+	+	+	
Abolghasmi 2011 ⁷	!	-	-	+	!	-	
Oxlund 2013 ⁸	+	!	+	-	!	-	

3. Supplementary Figure 2. Subgroup Analysis of Comparison between Spironolactone and Placebo on Blood Pressure in Type 2 Diabetes versus Non-Type 2 Diabetes Patients. (A) Systolic blood pressure. (B) Diastolic blood pressure.




(A)




(B)

4. Supplementary Figure 3. Subgroup Analysis of Comparison between Spironolactone and Placebo on Blood Pressure in Chronic Kidney Disease versus Non-Chronic Kidney Disease Patients. (A) Systolic blood pressure. (B) Diastolic blood pressure.




(A)




(B)

5. Supplementary Figure 4. Subgroup Analysis of Comparison between Spironolactone and Placebo on Blood Pressure in Heart Failure versus Non-Heart Failure Patients.
 (A) Systolic blood pressure. (B) Diastolic blood pressure.



(A)



(B)

References

1. Yang L, Zhang H, Cai M, et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. *Clin Exp Hypertens* 2016;38:464–8. <https://doi.org/10.3109/10641963.2015.1131290>; PMID: 27367159.
2. Václavík J, Sedlák R, Plachý M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. *Hypertension* 2011;57:1069–75. <https://doi.org/10.1161/HYPERTENSIONAHA.111.169961>; PMID: 21536989.
3. Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. *J Am Heart Assoc* 2020;9:e018827. <https://doi.org/10.1161/JAHA.120.018827>; PMID: 33222584.
4. Krasnińska B, Cofa S, Szczepaniak-Chicheł L, et al. The effects of eplerenone on the circadian blood pressure pattern and left ventricular hypertrophy in patients with obstructive sleep apnea and resistant hypertension – a randomized, controlled trial. *J Clin Med* 2019;8:1671. <https://doi.org/10.3390/JCM8101671>; PMID: 31614891.
5. Schneider A, Schwab J, Karg MV, et al. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension. *J Hypertens* 2017;35:1086–92. <https://doi.org/10.1097/HJH.0000000000001264>; PMID: 28118280.
6. Spence JD, Bogiatzi C, Kuk M, et al. Effects of eplerenone on resistance to antihypertensive medication in patients with primary or secondary hyperaldosteronism. *J Transl Int Med* 2017;5:93–9. <https://doi.org/10.1515/JTIM-2017-0020>; PMID: 28721341.
7. Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. *Saudi J Kidney Dis Transpl* 2011 Jan;22:75-8. PMID: 21196617.
8. Oxlund CS, Henriksen JE, Tamow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double-blind randomized clinical trial. *J Hypertens* 2013 Oct;31:2094-102. <https://doi.org/10.1097/HJH.0b013e3283638b1a>; PMID: 24107738.